Literature DB >> 21221557

Complication rates using balloon-expandable and self-expanding stents for the treatment of intracranial atherosclerotic stenoses : analysis of the INTRASTENT multicentric registry.

Wiebke Kurre1, Friedhelm Brassel, Roland Brüning, Jan Buhk, Bernd Eckert, Susanna Horner, Michael Knauth, Thomas Liebig, Jana Maskova, Dirk Mucha, Vojtech Sychra, Matthias Sitzer, Michael Sonnberger, Marc Tietke, Johannes Trenkler, Bernd Turowski, Joachim Berkefeld.   

Abstract

INTRODUCTION: Using balloon-expandable stents (BES) for treatment of intracranial stenoses, high inflation pressures and rigidity of the device are regarded as major drawbacks limiting feasibility and safety of the procedure. Self-expanding stents (SES) were developed to facilitate lesion access and to allow for less aggressive dilatation. We analyzed data of the INTRASTENT multicentric registry to assess whether self-expanding stents significantly reduced peri-interventional complication rates.
METHODS: Records of intracranial stent procedures were entered consecutively into the registry. Datasets were divided into two groups according to the type of stent used. For outcome measurement, we chose three categories: TIA/minor stroke [modified Rankin score (mRS) <2], disabling stroke, and patient death. Clinical outcome was compared between BES and SES. We analyzed types of adverse events occurring in each group in addition.
RESULTS: Of 409 atherosclerotic lesions, 254 were treated with BES and 155 with SES. Technical success rates were 97.6% and 98.7%, respectively. Adverse event rates were 4.9%, 3.7%, and 0.8% for TIA/nondisabling stroke, disabling stroke, and death in the BES group compared with 5.3%, 6.0%, and 4.0% in the SES group. The differences were not statistically significant. We observed more perforator strokes after use of BES, but thromboembolic events occurred more often in the SES treatment group.
CONCLUSION: Data of the INTRASTENT registry do not support the hypothesis that introduction of SES lowered the overall complication rate of intracranial stent procedures. There might be an advantage using self-expanding stents in vessel segments with important perforating arteries.

Entities:  

Mesh:

Year:  2011        PMID: 21221557     DOI: 10.1007/s00234-010-0826-y

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  19 in total

1.  Perforator stroke after elective stenting of symptomatic intracranial stenosis.

Authors:  W J Jiang; T Srivastava; F Gao; B Du; K H Dong; X T Xu
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

Review 2.  Use of stents to treat intracranial cerebrovascular disease.

Authors:  Philip M Meyers; H Christian Schumacher; Kurenai Tanji; Randall T Higashida; Louis R Caplan
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

3.  Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

Authors:  Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

4.  Short-term arteriographic and clinical outcome after cerebral angioplasty and stenting for intracranial vertebrobasilar and carotid atherosclerotic occlusive disease.

Authors:  T Mori; K Kazita; K Chokyu; T Mima; K Mori
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

5.  US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results.

Authors:  David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall
Journal:  Stroke       Date:  2007-02-08       Impact factor: 7.914

6.  A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease.

Authors:  David Fiorella; Michael M Chow; Michael Anderson; Henry Woo; Peter A Rasmussen; Thomas J Masaryk
Journal:  Neurosurgery       Date:  2007-08       Impact factor: 4.654

7.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

8.  Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis.

Authors:  W J Jiang; X T Xu; B Du; K H Dong; M Jin; Q H Wang; N Ma
Journal:  Neurology       Date:  2007-02-06       Impact factor: 9.910

9.  Treatment of intracranial atherosclerotic arterial stenoses with a balloon-expandable cobalt chromium stent (Coroflex Blue): procedural safety, efficacy, and midterm patency.

Authors:  Zsolt Vajda; Elina Miloslavski; Thomas Güthe; Elisabeth Schmid; Christoph Schul; Guido Albes; Hans Henkes
Journal:  Neuroradiology       Date:  2009-11-17       Impact factor: 2.804

10.  Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting.

Authors:  S Müller-Schunk; J Linn; N Peters; M Spannagl; M Deisenberg; H Brückmann; T E Mayer
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-25       Impact factor: 3.825

View more
  11 in total

1.  Value of imaging lenticulostriate arteries before middle cerebral artery stenting for the prevention of perforator stroke.

Authors:  Jian-Ren Liu; Min Zhang; Meng-Li Wei
Journal:  Neuroradiology       Date:  2012-07-10       Impact factor: 2.804

2.  Structural analysis for Wingspan stent in a perforator model.

Authors:  Motoaki Fujimoto; Yasuhiro Shobayashi; Koichiro Takemoto; Satoshi Tateshima; Fernando Viñuela
Journal:  Interv Neuroradiol       Date:  2013-09-26       Impact factor: 1.610

Review 3.  Off-label use of drugs and devices in the neuroendovascular suite.

Authors:  M M Abdihalim; A E Hassan; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-21       Impact factor: 3.825

Review 4.  Stenting in Intracranial Stenosis: Current Controversies and Future Directions.

Authors:  Arindam R Chatterjee; Colin P Derdeyn
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

Review 5.  Endovascular Therapy for Symptomatic Intracranial Artery Stenosis: a Systematic Review and Network Meta-analysis.

Authors:  Tao Wang; Kun Yang; Xiao Zhang; Jichang Luo; Ran Xu; Xue Wang; Yutong Yang; Xuesong Bai; Yan Ma; Yuxiang Yan; Liqun Jiao
Journal:  Transl Stroke Res       Date:  2022-02-12       Impact factor: 6.800

Review 6.  Diagnosis and Treatment of Intracranial Stenoses.

Authors:  W Reith; J Berkefeld; P Dietrich; J Fiehler; O Jansen
Journal:  Clin Neuroradiol       Date:  2015-09-04       Impact factor: 3.649

7.  [Treatment of high grade intracranial stenoses].

Authors:  P Dietrich; C Roth; A Simgen; D Junk; W Reith
Journal:  Radiologe       Date:  2012-12       Impact factor: 0.635

8.  Balloon-expandable stents for treatment of symptomatic middle cerebral artery stenosis: Clinical outcomes during long-term follow-up.

Authors:  Sung Hyun Baik; Hyo Sung Kwak; Gyung Ho Chung; Seung Bae Hwang
Journal:  Interv Neuroradiol       Date:  2018-07-10       Impact factor: 1.610

9.  Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis.

Authors:  Tao Wang; Jichang Luo; Xue Wang; Kun Yang; Vikram Jadhav; Peng Gao; Yan Ma; Na Zhao; Liqun Jiao
Journal:  Cochrane Database Syst Rev       Date:  2020-08-11

Review 10.  Role of stenting for intracranial atherosclerosis in the post-SAMMPRIS era.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  Biomed Res Int       Date:  2013-11-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.